Stifel upgrades biotech stock on a narrative shift in Alzheimer’s treatment

Stifel has upgraded Biogen (BIIB) to Buy from Hold, raising its price target to $202 from $144, signaling a potential upside of nearly 32%. Analyst Paul Matteis cited the stock's attractive valuation relative to peers and significant optionality, driven by an anticipated narrative shift in Alzheimer's treatment, including the scaling of lecanemab and upcoming preclinical study readouts, alongside potential tailwinds from its lupus drug pipeline, despite recent mixed business performance.

Analysis

Stifel has upgraded Biogen (BIIB) to a Buy rating from Hold, increasing its price target to $202 from $144, indicating a potential upside of nearly 32% from Wednesday's close. Analyst Paul Matteis justifies this upgrade by highlighting Biogen's attractive valuation, trading well below peers on an EV/sales basis, despite acknowledging mixed third-quarter results and an anticipated "just okay" fourth-quarter performance for its base business.

The core of Stifel's bullish stance is centered on significant optionality, particularly a projected narrative shift in Alzheimer's treatment. This includes the scaling of abeta antibodies like lecanemab, potential positive readouts from upcoming LLY and BIIB/Esai preclinical studies, and the anticipated approval of a lecanemab SQ formulation designed to ease treatment hurdles. Further tailwinds are expected from Biogen's lupus drug pipeline and a next-gen Alzheimer's program targeting tau.

This upgrade comes after a challenging period for Biogen, where its legacy business faced competitive pressures and the launches of lecanemab and skyclaris underperformed investor expectations. The stock has gained less than 1% year-to-date, significantly lagging the S&P 500's 15.6% advance, suggesting that these potential catalysts are currently undervalued by the market.

Key Decisions for Investors

• Investors should evaluate Biogen's long-term growth potential based on the anticipated Alzheimer's narrative shift and pipeline optionality, rather than solely focusing on near-term base business performance.
• Closely monitor upcoming preclinical study readouts for abeta antibodies (LLY, BIIB/Esai) and the regulatory progress of lecanemab's SQ formulation, as these are critical catalysts for stock re-rating.
• Consider Biogen's discounted EV/sales valuation relative to peers, assessing whether the current price adequately reflects the company's pipeline optionality and potential for future growth.